OptiPin
Eloralintide: uses, dosing & the facts
An investigational long-acting, selective amylin receptor agonist from Eli Lilly (development code LY-3841136), given as a weekly subcutaneous injection. Amylin is a hormone co-secreted with insulin that slows gastric emptying and signals satiety through the brainstem, so an amylin agonist reduces food intake by a different route than the GLP-1 drugs. It is in clinical trials for obesity and is not available outside them. This is an evidence-graded reference – what it is, what it's used for, typical reported dosing, half-life, side effects, and how to track it. It is educational, not medical advice or a recommendation to use a research compound.
- • Eloralintide – Fat loss. An investigational long-acting, selective amylin receptor agonist from Eli Lilly (development code LY-3841136), given as a weekly subcutaneous injection.
- • Commonly used for obesity and weight management (clinical trials only), appetite and satiety signalling via the amylin pathway, studied alongside and in combination with incretin drugs.
- • Half-life: Long-acting, engineered for once-weekly dosing. A precise published human half-life is not established..
- • Status: Research use only · not FDA-approved – an educational reference, not a dose protocol or sourcing advice.
What Eloralintide is
An investigational long-acting, selective amylin receptor agonist from Eli Lilly (development code LY-3841136), given as a weekly subcutaneous injection. Amylin is a hormone co-secreted with insulin that slows gastric emptying and signals satiety through the brainstem, so an amylin agonist reduces food intake by a different route than the GLP-1 drugs. It is in clinical trials for obesity and is not available outside them.
What Eloralintide is used for
- • Obesity and weight management (clinical trials only)
- • Appetite and satiety signalling via the amylin pathway
- • Studied alongside and in combination with incretin drugs
These are reported/community uses, not proven clinical outcomes. Most research peptides have limited human trial data behind such claims.
Typical reported dosing
| Injectable | Trial protocols use weekly subcutaneous dosing with a stepwise escalation. Published dose ranges are trial-specific and no consumer dosing schedule exists. Anything circulating as a protocol for this compound is not from a label. |
Presented as commonly-reported patterns for information only – not a dose recommendation. Eloralintide dosing is a decision for a qualified clinician.
Reconstitution
No consumer formulation exists. Trial material is supplied ready to use, so any reconstitution instructions circulating for this compound describe grey-market powder of unverified identity and content. The arithmetic is the same for any peptide: concentration = vial mg ÷ water mL, and on a U-100 syringe 100 units = 1 mL. Compute your own vial with the reconstitution calculator.
Half-life & cycling
Half-life: Long-acting, engineered for once-weekly dosing. A precise published human half-life is not established.. Half-life drives dosing frequency and how quickly the compound clears – see it plotted on the Eloralintide half-life calculator.
Cycling
Investigational. There is no established cycle: dosing outside a trial has no protocol behind it.
Side effects & warnings
- an injection site that turns red, hot or hard, spreads, weeps, or comes with a fever – same-day medical care – research-grade material carries no sterility guarantee, so abscess and cellulitis are the documented consequence
- swelling of the lips, tongue or throat, trouble breathing, or widespread hives after a dose – emergency care
- severe abdominal pain that bores through to the back and does not settle – urgent assessment for pancreatitis
- vomiting that stops you keeping fluids down – urgent care – dehydration is the common reason people on these compounds are admitted
- shaking, sweating, confusion or a racing heart, especially alongside insulin or a sulfonylurea – treat for low blood sugar and seek advice
- • Nausea and other gastrointestinal effects, the dose-limiting effect for amylin agonists
- • Injection-site reactions
- • Full safety profile is still being characterised in trials
Not approved by the FDA or any regulator, and not commercially available. It exists only in Eli Lilly's clinical programme, so material sold as eloralintide is not the trial drug and its identity, purity and concentration are unverified. Research use only. Discuss any weight-management decision with a qualified clinician.
Tracking Eloralintide in OptiPin
If you're tracking a Eloralintide protocol, OptiPin logs each dose with reminders and site rotation, charts the outcome you care about over your dose timeline, keeps per-vial inventory with runout warnings, and (where relevant) does the reconstitution math – all on-device, no account.
Log doses, outcomes & vials in OptiPin
Reminders, outcome-over-dose charts, vial runout warnings, and built-in reconstitution math – all on-device.
Download on the App StoreFAQ
What is Eloralintide?
An investigational long-acting, selective amylin receptor agonist from Eli Lilly (development code LY-3841136), given as a weekly subcutaneous injection. Amylin is a hormone co-secreted with insulin that slows gastric emptying and signals satiety through the brainstem, so an amylin agonist reduces food intake by a different route than the GLP-1 drugs. It is in clinical trials for obesity and is not available outside them.
What is Eloralintide used for?
Commonly discussed uses include: obesity and weight management (clinical trials only), appetite and satiety signalling via the amylin pathway, studied alongside and in combination with incretin drugs. These are reported uses, not proven outcomes or a recommendation.
How is Eloralintide dosed?
Commonly reported dosing: Injectable – Trial protocols use weekly subcutaneous dosing with a stepwise escalation. Published dose ranges are trial-specific and no consumer dosing schedule exists. Anything circulating as a protocol for this compound is not from a label.. This reflects patterns discussed in the community and is presented for information only, not as a dose recommendation – Eloralintide is not an approved medicine and dosing should involve a qualified clinician.
How do you reconstitute Eloralintide?
No consumer formulation exists. Trial material is supplied ready to use, so any reconstitution instructions circulating for this compound describe grey-market powder of unverified identity and content. On a U-100 syringe, 100 units = 1 mL. Concentrations vary by vial, so compute from your own vial with a reconstitution calculator.
What is Eloralintide's half-life?
Long-acting, engineered for once-weekly dosing. A precise published human half-life is not established.. Half-life shapes how often it is dosed and how quickly it clears.
What are Eloralintide's side effects?
Reported effects include: nausea and other gastrointestinal effects, the dose-limiting effect for amylin agonists, injection-site reactions, full safety profile is still being characterised in trials. Because it is a research compound, its safety profile is not fully characterized; discuss risks with a clinician.
Evidence & further reading
- Search the peer-reviewed literature for Eloralintide on PubMed (entry point to the primary evidence base, not a specific citation).
- Eloralintide on ClinicalTrials.gov – registered human trials, if any.
- US FDA / 503A compounding status of research peptides (2026).
- OptiPin peptides guide – categories, evidence grading, and how to run a protocol honestly.
Related
Frag 176–191 · MOTS-C · SLU-PP-332 · Tesofensine · Tirzepatide (Mounjaro/Zepbound) · Reconstitution calculator · All peptides